Clinical Trials Browser

Active not recruiting × lenvatinib × Gastrointestinal × Clear all

NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Phase 2 Active not recruiting

Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06187961 2026-05-22

CCGLC-011

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07581769 2026-05-14

Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging

Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07081633 2026-05-12

TREMENDOUS-2

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04887805 2026-04-29

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT05301842 2026-04-07

EMERALD-3

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Phase 1/2 Active not recruiting

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05113186 2026-01-29

LENVABLA

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04949256 2025-12-15

MK-7902-014

Phase 3 Active not recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

NCT05822752 2025-08-14

LIVIGNO-1

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06138769 2024-07-03

Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular